

Date: February 12, 2026

To: BC Hematologists and Oncologists

From: Stephen Yip, MD, PhD, FRCPC
Medical Director – Cancer Genetics & Genomics Laboratory

RE: New Rapid Test for *IDH1* Mutations

This letter is to inform you that effective **February 23rd, 2026**, the Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer - Vancouver will be offering a new rapid mutation test for somatic *IDH1* mutations in patients with newly diagnosed Acute Myeloid Leukemia (AML), facilitating the on-label use of ivosidenib (Tibsovo®). Testing is temporarily being funded through a pharmaceutical industry partnership in anticipation of regular funding through BC Cancer at a later date. A BC Cancer protocol for the use of ivosidenib with azacitidine for patients with *IDH1* mutated newly diagnosed AML is currently under review and development.

The rapid test for *IDH1* is:

- A targeted droplet digital PCR (ddPCR) assay that detects >99% of the commonly found mutations in *IDH1*.
- Only select *IDH1* codon 132 variants present at a VAF ≥ 1% will be reported.
- Turnaround time is ≤ 6 calendar days (from time of receipt of the sample at CGL to reporting).

How has testing changed?

IDH1 will now be included with the *FLT3* ITD/TKD and *NPM1* rapid mutation test for patients with a new diagnosis of AML. This testing will automatically be performed for all patients undergoing *FLT3* and *NPM1* testing. No additional requisitions are required to activate this testing.

What is detected by the Rapid *IDH1* Mutation test?

Consistent with Health Canada's approval of ivosidenib, this test will detect the 5 most common mutations in *IDH1* at codon 132 (R132C/H/G/L/S). Other mutations in *IDH1* that are not targeted by this assay can be detected by the more comprehensive myeloid panel.

Who qualifies for testing?

All newly diagnosed patients with AML will qualify for testing. Patients with relapsed or refractory AML are not eligible for testing. It remains that FLT3-ITD and FLT3-TKD testing remains available for Relapsed/Treatment Refractory AML.

How is the test ordered?

Rapid AML Mutation panel for *IDH1* mutations can be ordered using the CGL Myeloid Requisition [link](#).

What sample is required?

There are no changes to the sample requirements for patients eligible for the standard of care AML testing. The same sample submitted for *FLT3* and *NPM1* will be used for *IDH1*.

- 2 x 0.5 mL of bone marrow in EDTA (one for MRD testing (RNA) and one for Rapid AML Mutation Panel and Myeloid Panel (DNA))
- 1 x 20 mL of peripheral blood in EDTA (for MRD testing (RNA))
- Bone marrow aspirate in media for karyotype analysis and bone marrow aspirate in EDTA to Optical Genome Mapping (OGM). If available, should continue to be sent to the cytogenetics laboratory in your jurisdiction.

Where and how does the sample get sent?

Further information: <https://cancer geneticslab.ca/guidelines/specimens/#Shipping>

Cancer Genetics and Genomics Laboratory
BC Cancer - Vancouver
Room #3307 – 600 West 10th Avenue
Vancouver, BC
V5Z 4E6

Ship at room temperature – do not freeze.

Maximum transit time from collection: 7 days (DNA-based test).

Maximum transit time from collection: 48 hours (RNA-based test).

How will the test be reported?

The *IDH1* results (including allele fraction) are reported along with the rapid *FLT3* ITD/TKD and *NPM1* test into one single report. Note that the reportable limit for this assay is 1% (2% for R132L). Analytically positive results below this level will be reported as negative.

What is the expected turnaround time (TAT) for results?

The anticipated TAT is ≤ 6 calendar days from receipt of the sample and all required documentation (i.e., completed requisition and flow report confirming AML) in CGL.

How can I access the clinical report results for my patients?

The clinical report will be:

- Generated using the CGL SHIRE platform which is used for all CGL reporting
 - Uploaded electronically to CAIS, CST Cerner and CareConnect
 - For CareConnect information on how to view the report or to request access, [click here](#)
 - Mailed as a paper copy via Canada Post unless previously opted out
 - To discontinue receipt of the mailed paper copy, [complete this form](#)
-

Questions

Email: cancergeneticslab@bccancer.bc.ca

Website: <https://cancergeneticslab.ca/>

Stephen Yip, MD, PhD, FRCPC
Medical Director